VetStem tops 17,000 patient samples, nears 43,000 stem cell treatments

VetStem says it has processed more than 17,000 patient samples and delivered nearly 43,000 stem cell treatments for animals in the U.S. and Canada. The milestone underscores the company’s two decades in regenerative veterinary medicine and its push to expand treatment options for orthopedic and degenerative conditions.

Why it matters: - VetStem’s milestone signals broad use of regenerative veterinary medicine across dogs, cats, horses and other animals. - The company says more than 17,000 patient samples have translated into nearly 43,000 stem cell treatments. - The scale gives veterinarians another option for orthopedic and degenerative conditions, including osteoarthritis and tendon and ligament injuries.

What happened: - VetStem said it has processed more than 17,000 patient samples. - Those samples have resulted in nearly 43,000 stem cell treatments for animals in the United States and Canada. - The company marked the milestone in a Sept. 22, 2026 announcement from Poway, California. - VetStem said it has been providing stem cell processing services to veterinarians and their patients for more than 20 years.

The details: - VetStem’s patented technology isolates and concentrates regenerative cells from a patient’s own adipose, or fat, tissue. - VetStem Cell Therapy is primarily used for musculoskeletal conditions in dogs, cats and horses. - The therapy is used for osteoarthritis and injuries to tendons and ligaments. - VetStem has also worked with multiple exotic animal organizations to provide stem cell therapy for several exotic species. - VetStem was formed in 2002 to bring regenerative medicine to veterinary practice. - The company is based near San Diego and operates as a privately held biopharmaceutical enterprise. - VetStem also offers veterinarians an autologous stem cell processing service and other regenerative modalities. - The company holds its own patents and exclusive global veterinary licenses to a large portfolio of issued regenerative-medicine patents.

Between the lines: - The milestone suggests VetStem has built a durable clinical footprint in a niche that blends veterinary care with regenerative medicine. - The company’s emphasis on proprietary technology and patent licensing points to a strategy centered on differentiation and long-term defensibility. - Founder and CEO Dr. Bob Harman framed the milestone as evidence that veterinarians are increasingly trusting regenerative treatments for animal patients.

What’s next: - VetStem says it will keep investing in research, innovation and collaboration with the veterinary community. - The company is focused on developing new clinically practical and affordable veterinary solutions. - VetStem aims to expand how regenerative therapies can help improve animal health.

The bottom line: - VetStem is using scale, long operating experience and proprietary technology to reinforce its role in regenerative veterinary medicine.